Clareo Health | A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants are able to comply with the process of the protocol.
Men or women greater than or equal to 18 years
At least one measurable lesion in accordance with RECIST 1.1
Must have an ECOG performance status of 0 or 1.
Must have adequate laboratory parameters.
Patients with advanced solid tumors who have failed after adequate standard treatment, are intolerant to standard treatment, or have no standard treatment available.
Documentation of the presence of a KRAS G12C mutation
Reproductive-age women agree to use adequate contraception and cannot breastfeed while participating in this study and for a period of 6 months after the last dose.Men also consent to use adequate contraceptive method within the same time limit.
You may not be if
Participants with tumors known to harbor molecular alterations for which targeted therapy is locally approved, except for KRAS G12C.
Treatment with any of the following: Previous or current treatment with other KRAS G12C inhibitors.
Active brain metastases.
Participants with uncontrolled pleural, ascites or pericardial effusion
History of other primary malignancies.
Abnormal cardiac examination results.
Severe, uncontrolled or active cardiovascular disorders.
Uncontrolled hypertension.
Severe bleeding symptoms or bleeding tendencies.
Severe arteriovenous thrombosis occurred
Serious infection.
Continuous use of glucocorticoids
Active infectious diseases.
Refractory nausea, vomiting, or chronic gastrointestinal diseases, or inability to swallow oral medications
